Conversion of shares in RaySearch Laboratories AB (publ)

During November 2015, 1,061,577 Class A shares were converted to Class B shares, at the request of a shareholder. The total number of votes in RaySearch thereafter amounts to 126,648,099 votes. The total number of registered shares in RaySearch amounts to 34,282,773 shares, of which 10,262,814 are Class A shares and 24,019,959 are Class B shares.

According to RaySearch Laboratories AB (publ)’s Articles of Association, owners of Class A shares have the right to have such shares converted to Class B shares. A conversion reduces the number of votes in the company. When a conversion has been carried out, RaySearch is obligated by law to disclose information on the changes occurred by the conversion.

About RaySearch

RaySearch Laboratories AB (publ) is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch markets the RayStation® treatment planning system to clinics all over the world. In addition, RaySearch’s products are distributed through licensing agreements with leading medical technology companies. RaySearch’s software solutions are used by over 2,600 clinics in more than 65 countries. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.

For more information about RaySearch, visit

For further information please contact: RaySearch Laboratories AB (publ)

Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00

RaySearch discloses the information provided herein pursuant to the Securities Market Act and/or the Financial Instruments Trading Act.

About Us

RaySearch Laboratories AB (publ) has been pushing the limits of advanced cancer treatment since 2000. Using progressive algorithms, RaySearch develops world leading software used by thousands of the most cutting-edge cancer clinics in the world. The algorithms are based upon founder and CEO Johan Löf’s scientific knowledge, acquired during his PhD on radiation treatment of moving tumors at the Karolinska Institute. The treatment planning system RayStation and the OIS RayCare are the result of extensive development during years of research, and today used to improve chances of survival and quality of life for cancer patients. We fight for a world where cancer is conquered.


Documents & Links